• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Microbiol . Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome corona

tetano

Editor, Senior Moderator
Front Microbiol


. 2022 Nov 3;13:999783.
doi: 10.3389/fmicb.2022.999783. eCollection 2022.
Performance evaluation of a new on-demand molecular test for the rapid identification of severe acute respiratory syndrome coronavirus 2 in pediatric and adult patients


Luna Colagrossi[SUP] 1 [/SUP], Valentino Costabile[SUP] 1 [/SUP], Rossana Scutari[SUP] 1 2 [/SUP], Valeria Cento[SUP] 3 4 [/SUP], Luana Coltella[SUP] 1 [/SUP], Antonino Reale[SUP] 5 [/SUP], Martina Scilipoti[SUP] 5 [/SUP], Alberto Villani[SUP] 5 [/SUP], Claudia Alteri[SUP] 1 2 [/SUP], Carlo Federico Perno[SUP] 1 [/SUP], Cristina Russo[SUP] 1 [/SUP]



Affiliations

Abstract

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has increased the need to identify additional rapid diagnostic tests for an accurate and early diagnosis of infection. Here, we evaluated the diagnostic performance of the cartridge-based reverse transcription polymerase chain reaction (RT-PCR) test STANDARD M10 SARS-CoV-2 (SD Biosensor Inc., Suwon, South Korea), targeting the ORF1ab and E gene of SARS-CoV-2, and which can process up to eight samples in parallel in 60 min. From January 2022 to March 2022, STANDARD™ M10 assay performance was compared with Xpert[SUP]®[/SUP] Xpress SARS-CoV-2 (Cepheid, Sunnyvale CA) on 616 nasopharyngeal swabs from consecutive pediatric (N = 533) and adult (N = 83) patients presenting at the "Istituto di Ricovero e Cura a Carattere Scientifico" (IRCCS) Ospedale Pediatrico Bambino Gesù, Roma. The overall performance of STANDARD M10 SARS-CoV-2 was remarkably and consistently comparable to the Xpert[SUP]®[/SUP] Xpress SARS-CoV-2 with an overall agreement of 98% (604/616 concordant results), and negligible differences in time-to-result (60 min vs. 50 min, respectively). When the Xpert[SUP]®[/SUP] Xpress SARS-CoV-2 results were considered as the reference, STANDARD™ M10 SARS-CoV-2 had 96.5% sensitivity and 98.4% specificity. STANDARD M10 SARS-CoV-2 can thus be safely included in diagnostic pathways because it rapidly and accurately identifies SARS-CoV-2 present in nasopharyngeal swabs.

Keywords: COVID-19; RT-PCR testing; SARS-CoV-2; comparative diagnostic accuracy; molecular diagnosis.
 
Back
Top Bottom